Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia

• DOI: 10.1111/jch.14153
• Publication Date: 2021-01-06T12:58:33Z
• Authors: Kazuomi Kario; Masafumi Nishizawa; Mari Kiuchi; Arihiro Kiyosue; Fumishi Tomita; Hiroshi Ohtani; Yasuhisa Abe; Hideyo Kuga; Satoshi Miyazaki; Takatoshi Kasai; Makiko Hongou; Takanori Yasu; Jin Kuramochi; Yoshihiro Fukumoto; Satoshi Hoshide; Ichiro Hisatome
• Keywords: Febuxostat; Xanthine oxidase inhibitor

Abstract Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce levels and have several other potential effects. This multicenter, randomized, open‐label study compared the effects of two XORi, topiroxostat febuxostat, on arterial stiffness, levels, BP hypertensive hyperuricemia. Patients received 40–160 mg/day or febuxostat 10–60 mg/day, titrated to maintain <6 mg/dl, for 24 weeks. The primary endpoint was change cardio‐ankle vascular index (CAVI) from baseline There were no significant changes CAVI weeks (from 9.13 9.16 [feboxustat] 8.98 9.01 [topiroxostat]). Compared baseline, there reductions (–2.9 –2.5 mg/dl; both p < 0.001) morning home systolic (–3.6 –5.1 mm Hg; 0.01) after weeks' treatment topiroxostat. decreased greatest extent subgroup uncontrolled at baseline. Topiroxostat, but not significantly plasma xanthine activity versus urinary albumin‐creatinine ratio (UACR) (–20.8%; = 0.021), (–8.8%; 0.362). In conclusion, neither nor had any stiffness over treatment.